Mechanistic Insights into Sperm cAMP Signaling: Relevance for Male Infertility and Contraceptive Development

A narrative review maps the cAMP signaling cascade that triggers sperm capacitation — and flags it as a dual target for infertility treatment and non-hormonal male contraception

Journal: Cellular Signalling | Published: 2026-03-23 | Type: Review | PMID: 41881091 Authors: Luque GM, Stival C, Oscoz-Susino N, Krapf D, Buffone MG, Marín-Briggiler CI (Instituto de Biología y Medicina Experimental / Instituto de Biología Molecular y Celular de Rosario, CONICET, Argentina) Funding/COI: Funding not disclosed. Three of six authors (Buffone MG, Krapf D, Luque GM) are shareholders of Fecundis, a company with commercial interests in the fertility space. The remaining three authors declare no conflicts.

Summary

Sperm can't fertilize an egg straight out of the epididymis — they need to undergo capacitation, a biochemical activation process triggered after entering the female reproductive tract. This review synthesizes a decade of research on how cyclic adenosine monophosphate (cAMP) drives that process, from the enzyme that makes it (soluble adenylyl cyclase, sAC) through protein kinase A (PKA) downstream to hyperactivated motility and the acrosome reaction. The authors argue the same pathway is a viable target from two opposite directions: boost it to treat infertility, block it for non-hormonal male contraception.

Claims

• cAMP concentration rises sharply during early capacitation, driven by sAC activation
• sAC is activated canonically by bicarbonate and calcium; the review documents emerging non-canonical regulatory mechanisms
• The sAC/cAMP/PKA axis modulates both hyperactivated flagellar motility and acrosomal exocytosis — the two functional outputs required for fertilization
• The relationship between the sAC/cAMP/PKA pathway and CatSper (the principal sperm calcium channel) is described as "complex and sometimes controversial"
• The review identifies downstream cAMP effectors beyond PKA as under-characterized
• The authors assert the pathway has therapeutic potential in both directions: pharmacological activation for male infertility, pharmacological inhibition as a non-hormonal contraceptive

Study Quality

This is a narrative review, not a systematic review. There is no stated search strategy, no defined inclusion/exclusion criteria, and no quality assessment of the underlying studies. That makes it a synthesis of the authors' reading of the literature — useful for orientation, but inherently selective. The authors focus on the last decade, which is a reasonable scope for a fast-moving molecular biology field, but the lack of methodology means readers cannot assess what was left out.

The mechanistic content appears rigorous in framing — the review distinguishes canonical from non-canonical regulation, acknowledges controversy around CatSper interactions, and flags gaps in knowledge about downstream effectors. That intellectual honesty partially offsets the informal review structure.

Red Flags

• Undisclosed funding in a review where three of six authors are shareholders of a fertility company (Fecundis). Commercial interest in validating this pathway as a therapeutic target is direct and unmitigated.
• Narrative review design: no systematic search, no PRISMA flow, no quality scoring of cited studies. The selection of papers supporting a coherent mechanistic story may not reflect the full weight of evidence.
• Dual-use framing (treat infertility AND enable contraception) reads as market expansion logic — the same pathway, two products — rather than a clinically derived need.
• No human clinical data cited in the abstract; the review draws heavily on animal models and in vitro studies, whose translational relevance to human infertility is not established here.
• The acrosome reaction and hyperactivated motility are described as modulated by cAMP, but effect sizes and whether cAMP manipulation moves clinically meaningful endpoints (fertilization rates, live birth rates) are not addressed.

Strengths

• Covers methodological advances in measuring cAMP dynamics — useful for researchers designing experiments in this area
• Acknowledges the CatSper/cAMP controversy rather than papering over it
• Explicitly flags non-canonical regulatory modes as emerging, signaling intellectual honesty about the limits of current models
• Argentine CONICET groups are among the most productive in mammalian sperm biology; the author list carries genuine domain expertise

Verdict

This review is a competent overview of sperm cAMP biology written by people who clearly know the field — and who also have financial stakes in commercializing it. That conflict doesn't make the science wrong, but it should make you read the therapeutic framing critically. The mechanistic content is the useful part; the translational claims (fix infertility, enable contraception) are aspirational and unsupported by clinical data presented here. Researchers entering this area will find it a useful orientation to the literature; clinicians and patients should note it contains no human trial data and no evidence-based treatment conclusions. The missing funding disclosure is a journal-level failure that should have been caught in review.